After a Bsc in Biostatics (University of the West of England, Bristol, GB) and a professional license in Biostatistics passed at Joseph Fourier University (Grenoble, France), Aurélia Meurisse became a clinical data manager for Contract Research Organizations (CRO).

After working for 13 years for CRO in Grenoble and Dijon she decided to join the Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon as a clinical data manager. Her main activities consist in managing data bases for clinical studies promoted by the hospital of Besançon (administrative procedures, data-management activities from creation of case report form to database lock, including data validation and coding of medical terms) and providing support to medical students for their thesis (creation of data bases, data import).

According to her initial training, she punctually produces statistical analysis for Phase II studies (descriptive statistics, survival analysis).

As part of the collaboration with the GERCOR, she provides methodological advices and critical review of documentation related to clinical trials data-management.

Main areas of expertise:

- Clinical data-management

- Meta-bases

Main ongoing external collaborations:

- GERCOR

Tools online

- Flow-chart of data-management process (for clinical studies)

- Data-management process (for medical students) 

Main publications

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst

Latest publications

sample

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Dr. Angélique VIENOT
Journal name : Int J Cancer

sample

AbstractObjectives: To assess health-related quality of life (QoL) in caregivers of elderly patients with chronic...

Posted by : Mme. Aurélia MEURISSE
Journal name : Int J Public Health

sample

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Cancers

sample

AbstractPurpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : J Clin Oncol

sample

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posted by : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Trials

sample

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posted by : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Dig Liver Dis

sample

Background Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic...

Posted by : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Journal name : Lancet Gastroenterology Hepatology

sample

AbstractKeywords: Adjuvant; Chemotherapy; Colon cancer; Guidelines; Randomised controlled trials; Time-to-event...

Posted by : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Eur J Cancer

sample

AbstractBackground: There is a strong rational of using anti-programmed cell death protein-1 and its ligand...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Front Oncol

sample

AbstractAflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the...

Posted by : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Journal name : Int J Oncol .

Latest News

Latest tools

Evaluation de la réponse tumorale (Nouveaux critères RECIST v 1.1)“New response evaluation criteria in solid...

Posted by : Mme. Aurélia MEURISSE

Posted by : Mme. Aurélia MEURISSE

2015-2023 © Copyright - UMQVC.org

Website by Pearlweb